Prosecution Insights
Last updated: November 20, 2026
Application No. 18/836,681

SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME

Final Rejection §102§103§112§DOUBLEPATENT
Filed
Aug 07, 2024
Priority
Feb 08, 2022 — provisional 63/307,926 +1 more
Examiner
CHANDRAKUMAR, NIZAL S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Vertex Pharmaceuticals Incorporated
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
1303 granted / 1794 resolved
+12.6% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
91 currently pending
Career history
1900
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
36.8%
-3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1794 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Amended claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-59, 61, 63, 65, 78, 79 are pending. Claim Rejections – Improper Markush Group The nonstatutory Markush grouping rejection is based on a judicially approved “improper Markush grouping” doctrine. Previously presented rejection of claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-59, 61, 63, 65, 79 are rejected on the judicially-created basis that it contains an improper Markush grouping of alternatives is maintained. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). The improper Markush grouping includes species of the claimed invention that do not share both a substantial structural feature and a common use that flows from the substantial structural feature. A Markush claim contains an “improper Markush grouping” if: (1) the species of the Markush group do not share a single structural similarity,” OR (2) the species do not share a common use. Members of a Markush group share a "single structural similarity” when they belong to the same recognized physical or chemical class or to the same recognized physical or chemical class or to the same art-recognized class. Members of a Markush group share a common use when they are disclosed in the specification or known in the art to be functionally equivalent (see Federal Register, Vol. 76, No. 27, Wednesday, February 9, 2011, p. 7166, left and middle columns, bridging paragraph). This rejection applies to the definition of the multiple moieties in the claimed monomer. These moieties are broad and divergent in nature. The compounds do not even belong to a recognized class of compounds because every variable varies having complex meanings and endless permutations and combinations. The members of the recited Markush group are so disparate chemically as not to be members of a recognized chemical class of compounds. Further the point of attachment and how these are linked to each render the conceivable compounds structurally different and uncommon. In view of these claimed elements and the divergent substitutions on the above groups, the physical and chemical properties of claimed compounds are going to be different. Applicants’ may have to establish the core structure for their claimed compound. It cannot be said that all members of the Markush group have a single structural similarity, based on the above described structural differences. Specifically, the species of the Markush group do not share a “single structural similarity” because there are no required structural features within each variable definition such that each member of the group would have at least one structural feature, which feature is essential to the activity/function of the claimed compounds, in common. In addition alternatively usable member of the Markush group, for example, the inhibitors or binders of different enzymes, does not share a common use, absent evidence to the contrary. The question of whether the lack of a specific statutory basis is a fatal flaw against a holding of an Improper Markush group was decided in In re Harnish, 206 USPQ 300, 305, where the court said, “…we think it should be clear from our actions in Weber and Haas II that we there recognized the possibility of such a thing as an "improper Markush grouping." We were and are aware that it does not have a specific statutory basis …” The court went on to reverse the rejection, (which had been made by the Board under Rule 196(b)) but not on the lack of a specific statutory basis but rather, “Clearly, they are all coumarin compounds which the board admitted to be "a single structural similarity." We hold, therefore, that the claimed compounds all belong to a subgenus, as defined by appellant, which is not repugnant to scientific classification. Under these circumstances we consider the claimed compounds to be part of a single invention so that there is unity of invention…” Thus, the rejection was overturned not because of any lack of a specific statutory basis, but because of the specific facts in the case. The Markush group was held proper in that case, as was the case also in Ex parte Price 150 USPQ 467, Ex parte Beck and Taylor, 119 USPQ 100, and Ex parte Della Bella and Chiarino 7 USPQ2d 1669. Cases where the Markush group was held improper include Ex Parte Palmer, 7 USPQ 11, In re Winnek, 73 USPQ 225, In re Ruzicka, 66 USPQ 226, Ex parte Hentrich, 57 USPQ 419, Ex parte Barnard, 135 USPQ 109, Ex parte Reid, 105 USPQ 251, Ex parte Sun and Huggins, 85 USPQ 516, In re Thompson and Tanner, 69 USPQ 148, In re Swenson, 56 USPQ 180, and In re Kingston, 65 USPQ 371. Note In re Milas 71 USPQ 212 in which the structural difference between vitamin A and D was sufficient to uphold the improper Markush rejection. Also see In re Winnek 73 USPQ 225 and In re Ruzicka 66 USPQ 226 in which structural differences were small and yet a similar holding was maintained. All these cases involved compounds in the pharmaceutical art known to be structure-sensitive. Of particular interest is Ex Parte Hozumi, 3 USPQ2d 1059, which reversed an improper Markush rejection “in view of the relatively large proportion of the structure of the compounds in the claimed class which is common to the entire class”. Here, by contrast, the amount in common is none. In response to this rejection, Applicant should either amend the claim(s) to recite only individual species or grouping of species that share a substantial structural feature as well as a common use that flows from the substantial structural feature, or present a sufficient showing that the species recited in the alternative of the claims(s) in fact share a substantial structural feature as well as a common use that flows from the substantial structural feature. This is a rejection on the merits and may be appealed to the Board of Patent Appeals and Interferences in accordance with 35 U.S.C. §134 and 37 CFR 41.31(a)(1) (emphasis provided). Response to Remarks: Amendments to claims and Applicants arguments are not persuasive. Applicants argue that the claimed compounds share ‘substantial structural feature’ (invariable) and common sue. This is not persuasive for the following reasons. The only at once recognizable structural feature is the phenyl ring and piperidine ring. Consider for example the ring B defined as PNG media_image1.png 90 576 media_image1.png Greyscale Because both are heterocyclic groups, that an unsubstituted a three membered B ring epoxide and a multiply substituted B ring 12 membered heterocyclic group with several heteroatoms share same structural feature is not persuasive. Further as evidenced by data in the Table 20, structurally similar compounds do not share similar cell proliferation properties (which ultimately needed for intended common use). Also see section under 112-1. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Previously presented rejection of claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-58, 61, 63, 65 and 79 rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making few compounds, does not reasonably provide enablement for plethora of conceivable possibilities of formula I is maintained for reasons of record. Applicant’s arguments are persuasive with respect to some of the issues raised, for example with respect to macromonomer. Applicants argument that the claims can have inoperative elements is not persuasive. How much of the inoperative and operative elements that the claims contain(s) is/are the issue at hand. Further that the specification provides (see Remarks page 53 first full paragraph) extensive guidance, direction and working examples is not persuasive. Consider for example, A substituted with more than one of any of the R1 groups. That any and all R1 groups can be formed does not find support finds little support in the specification. Consider, for example, the disclosure at page 78 onwards. This relates to the vast majority of the compounds made by the alkylation of piperidine N. The page 78 method to make compound with R1=Cl (at a specific location on the PNG media_image2.png 266 640 media_image2.png Greyscale PNG media_image3.png 290 570 media_image3.png Greyscale phenyl A ring, to make any and all PNG media_image4.png 24 208 media_image4.png Greyscale Similarly page 111 also discloses chemistry which is predicated on the Pd catalyzed reaction (removal of Br from starting material). As such any and all R1s including R1=any halogen just not enabled in this Scheme at page 111 or at page 78 scheme. Consider for example, X=Y=CO; or X=CO and Y= CH2 with and Z=S, N or O; Similarly, as to claims it is not seen where specification discloses compounds with Z being PNG media_image5.png 22 184 media_image5.png Greyscale . What deuterated derivative or C5=C9 aryls are intended here. How are these made. These just cannot be willed into existence There is no disclosure as to how to procure such compounds of starting materials that could be substituted in the disclosed Schemes as the ones disclosed above that would predictably make the claimed compounds. That 3-memebered heterocycles are C7-C9 aryls is raises major chemistry issues, for example, the 3-memebered epoxide or thioperoxide could be B rings as part of druggable compounds cannot be supported, since these are alkylating agents. Likewise, that the C7 aryl, tropylium cation can be attached to N of piperidine raises issues of makeability Also see section under Claim Rejections – Improper Markush Group. In this context, the following at page 4 in the document filed P.237.Receipt Date 08/07/2024, PNG media_image6.png 300 516 media_image6.png Greyscale is revealing and just cannot be overlooked. Regardless of the above, the Issue here is combination of different possibilities of the alphaphets of the pictured formula. That all the different generically recited groups decorating the invariable core structures, are usable in interchangeable manner for predictable use defies commonsense with regards to structure and function, taught by the cited Venkatesh, Cannon, Sundaresan and biological principles and also as per Friedman, Jeganathan citations for the intended use. Applicant is not responsive to any of these teachings. As noted earlier, there is no structural guidance such as pharmacophore definition disclosed in the specification to guide one of skill in the art to choose from the plethora possibilities recited for the variables. Predictable use is the issue here. As per the data in the Table 20 of the 314 compounds tested some are structurally similar compounds show a widely different IP50 values ranging from <50 nM to >500 nM. The disclosed results reflect predictability in the art that is/are consistent with the teachings of the multiple prior art references discussed in the previous action. Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001, states “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “[p]atent protection is granted in return. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-58, 61, 63, 65, 78, 79 are rejected under 35 U.S.C. 103 as being unpatentable over Ray, ACS Omega (2021), 6(3), 2284-2311; Makinngs, US8258148, Takai, Bioorg.Med.Chem.Lett.24(2014) 3189–3193; Guardia, J. Med. Chem. 2018, 61, 11327−11340; Kenichi, Journal of Medicinal Chemistry (2019), 62(7), 3407-3427 and US11976067 (provisional priority 01/18/2022), Guardia, Journal of Medicinal Chemistry (2018), 61(24), 11327-11340 and Foye’s Principles of Medicinal Chemistry, 7th Edition, page 53 column B and Walsh J. Med. Chem. (1989) 32 (1): 105–118. In view of amendments to claims, Foye ,Ray, Makinngs, Guardia and Kenichi (found already in the file wrapper), added here to augment previously presented rejection. Specific responses to Applicant’s Remarks with regards to issued US patent is found following the reformatted rejection. Ray at page 2286, Table 2: PNG media_image7.png 374 530 media_image7.png Greyscale X=O, Y=Z=R1a=R1b=H, instant A decorated with recited R1 is seen as R1 above B = 5-memebered heteroaryl with Ra = 6-membered aryl Guardia at page 11329 in Table 2, teaches pharmaceutically active thiophene (in red) and other heterocycle compounds, as well as instant invariable template of the instantly claimed formula. See Figure 1 at column A of 11328. PNG media_image8.png 188 138 media_image8.png Greyscale Likewise, Ray pages 2285, Tables 1-3 teach compounds falling under the scope of the instant formula (see section under 35 USC § 102). Similarly, Takai page 3191 Table 1 and at page 3192 chemistry scheme teaches how to make (using elementary N-alkylation chemistry methods biologically active compounds having the core structure PNG media_image9.png 78 86 media_image9.png Greyscale Kenichi, in Scheme 3, also teaches compounds similar to compounds of claimed formula. PNG media_image10.png 68 340 media_image10.png Greyscale Compare compound 45 (deliberate) Claim 35 is Makinngs, teach PNG media_image11.png 134 546 media_image11.png Greyscale PNG media_image12.png 132 244 media_image12.png Greyscale The numbers in the above are Chemical Abstracts Registry numbers. X=CH2; Y=Z=CH2 B is heterocycle; R1= halogen Makings also teaches compound at column 209, line 28-29; Also see Table 1 at column 32 to column 183 and in claims at column 267 to column 374. US11976067 teaches claims column 1362-1524 compounds similar to the instant formula as explained below: Compare US11976067 claim 1 formula: PNG media_image13.png 228 198 media_image13.png Greyscale With entry 1, 6, 13 and 26 PNG media_image14.png 184 180 media_image14.png Greyscale PNG media_image15.png 148 176 media_image15.png Greyscale PNG media_image16.png 150 142 media_image16.png Greyscale PNG media_image17.png 178 124 media_image17.png Greyscale of independent claim 78 (which does fall under the scope of base claim 1 Z = CO; R1c of NR1c is H and Z is bond) are similar to the compounds of formula of claims of US11976067 (see dependent claims species in US11976067). Also compare bottom of instant claim 9 at claim page 10. The difference is the presence of L2 in formula of claim 1 US11976067. In US11976067 is PNG media_image18.png 22 152 media_image18.png Greyscale . That is the R4 CH2 in instant formula is linked to the B ring. Otherwise, there is extensive overlap in the claims. See Walsh, see Table IV at page 110 for such routine modifications (O, NR for CH2). The instantly claimed compounds are similar to pharmaceutically active compounds in the above cited prior art references. (Also see the structural correlation for anticipation under section 102) This is further explained below: . Interchangeable use of thiophene and pyridine for instant (instant A = phenyl (ene) (euphemistically recited as 6-memebered aryl) in the cited references themselves. See pictured Ray Table. Also bioisoteric replacement of thiophene for phenyl ring is explicitly taught in the teachings of Foye at page 53 column B. PNG media_image19.png 519 492 media_image19.png Greyscale Foye also teaches F (claimed R1) replacement of H (of many compounds in the cited prior art). The position taken is that the instant claimed formula limitations represent selective combination of prior art elements, recited with efforts to avoid rejection under anticipation. An example in this regard is the Kenichi compounds pictured above. This reference is not anticipatory for the limitation of dependent claim 35, because, the Kenichi in compound PNG media_image20.png 88 118 media_image20.png Greyscale the PNG media_image21.png 24 46 media_image21.png Greyscale part is not in claim 35 for R1c. However this PNG media_image22.png 36 54 media_image22.png Greyscale , is interchangeably useable for H and alkyl, (recited for multiple R groups in the claims as equivalents) as per compounds of independent claim 78 (see entry 41, 42 and 45). The limitations of the method claims 58, 61, 63, 65 relate to the inherent property of the compounds about which the cited references are silent. Also note that As MPEP 2112 Requirements of Rejection Based on Inherency; Burden of Proof [R-10.2019], "[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer." As per MPEP 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers) [R-01.2024]; A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Further the above pointed out difference, CH2 replacement for O can be argued as ‘bioisosteric replacement’. See for example, Foye’s Principles of Medicinal Chemistry, 7th Edition, page 53 column B. It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit since each is well known in the art for their beneficial properties. Again, the invention is a selective combination of the inventions by the prior arts done in a manner obvious to one of ordinary skill in the art. Patent for the combination of known elements wherein their functions remain the same withdraws “what is already known into field of its monopoly and diminishes resources available to skilled men”. Sakraida v. Ag Pro, Inc.189 USPQ 449, 425 US 273, (1976). A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Obviousness can be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (In re Opprecht 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); In re Bode 193 USPQ 12 (CCPA) 1976). In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. The Supreme Court in KSR International Co. v. Teleflex Inc., 550 U.S. 398, 127 S. Ct. 1727, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper “functional approach” to the determination of obviousness as laid down in Graham. The key to supporting any rejection under 35 U.S.C. 103 is the clear articulation of the reason(s) why the claimed invention would have been obvious. The Supreme Court in KSR noted that the analysis supporting a rejection under 35 U.S.C. 103 should be made explicit. Exemplary rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Note that the list of rationales provided is not intended to be an all-inclusive list. Other rationales to support a conclusion of obviousness may be relied upon by Office. Obviousness can be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. Accordingly, the claims do not recite an unobvious distinction over the prior art. Further, a reference is relevant not only for what it expressly teaches, but also for what it would have conveyed to one of ordinary skill in the art. See In re Opprecht, 12 USPQ2d 1235, 1236 (Fed. Cir. 1989); In re Bode, 193 USPQ 12 (CCPA 1976). In light of the foregoing discussion, the Examiner finds that the claimed subject matter as a whole would have been obvious to one of ordinary skill in the art at the time the invention was made, in view of the cited references and the knowledge generally available in the art. Accordingly, the claims are rejected under 35 U.S.C. § 103. Response to Applicant Remarks: Applicant’s arguments focus on the Examiner admitted to the difference L2 (see previous action page 14, line 6 from the bottom!). For addition medicinal chemistry examples for use of CH2 for O or NR, see Walsh, J. Med. Chem. (1989) 32 (1): 105–118, Table 4. Argument that the office has not articulated any reason for modification by osa (see page 42 last paragraph of Remarks). Further Applicant notes that the pointed out Foye does not teach the Examiner statements (with supporting Text Book reference) with regards to replacements and modifications. Parenthetically it is interesting to note that claim limitations for the alphaphets of claimed Formula 1, such modifications!. Applicant’s statements clearly reflects Applicant’s allegation of improper office action. This Examiner strongly encourages Applicant to contact Examiner’s Supervisor (SPE), because especially this specific Supervisory Patent Examiner is a big proponent of consideration of ‘bioisoteric replacement’ in obviousness analysis. Further such actions on the part of the Applicant is anticipated to facilitate compact of prosecution. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ray, ACS Omega (2021), 6(3), 2284-2311 Ray at page 2286, Table 2: PNG media_image7.png 374 530 media_image7.png Greyscale X=O, Y=Z=R1a=R1b=H, instant A decorated with recited R1 is seen as R1 above B = 5-memebered heteroaryl with Ra = 6-membered aryl Claim(s) 1, 5, 9, 11, 15, 16, 23, 37, 54, 56, 57 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated, Makinngs, US8258148. Makinngs, teach PNG media_image11.png 134 546 media_image11.png Greyscale PNG media_image12.png 132 244 media_image12.png Greyscale The numbers in the above (and also see below) are Chemical Abstracts Registry numbers. X=CH2; Y=Z=CH2 B is heterocycle; R1= halogen Makings also teaches compound at column 209, line 28-29; Also see Table 1 at column 32 to column 183 and in claims at column 267 to column 374. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Amendment to claims and to augment the previously presented rationale new references are invoked. Claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-58, 61, 63, 65, 78, 79 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1,4,6-7,10-11,18,22-24,29,33 and 35 and method claims 36, 37, 44-49 of copending Application No. 18714031 (reference application) is maintained for reasons of record. Note that the entirety of references cited under Claim Rejections - 35 USC § 103 And Claim Rejections - 35 USC § 102 is invoked here in the obviousness analysis as per Graham v. John Deere Co., 383 U.S. 1 (1966). That is prior art teachings discussed sections under Claim Rejections - 35 USC § 103 and Claim Rejections - 35 USC § 102 are known to one of skill in the art when faced with subject matter of conflicting claims. Applicant points out the NH of piperidine is unsubstituted in the conflicting claims. This is not persuasive, because, not only the NH compounds (of the conflicting claims) are synthetic intermediate for making the instant claims and in the secondary references, it is routine in the drug discovery research to test in identifying the minimum structural requirement (pharmacophore) needed for (the same) intended use. This is also evidenced by the disclosure at the point out Takai.Bioorg.Med.Chem.Lett.24(2014) 3189–3193, Table 3191, entry 2. and disclosure in US9346805 NH and N-substituted compounds. Also see Abdelshaheed, Piperidine nucleus in the field of drug discovery, Futur J Pharm Sci. (2021) 7:188, 1-11. Previously presented rejection of claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-58, 61, 63, 65, 78, 79 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-55 of U.S. Patent No. 11866446 and claims 1-23 of U.S. Patent No. 12421249 is maintained. Applicant points out what was already discussed in the previous action with regards to thiophene and the N-alkylation modification. Obviousness of this bioisosteric modification is discussed under section 103 with Text Book references. Also see cited references for rejection over the claims of US Application No. 18714031. Likewise (Likewise means for the same rationale discussed above), claims 1, 5, 9, 11, 15, 16, 23, 35, 37, 44, 52, 54, 56-58, 61, 63, 65, 78, 79 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No US12421249. The art made of record and not relied upon is considered pertinent to applicant's disclosure. Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs June 2022 41:6, 801-804 Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324–330. THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Aug 07, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §102, §103, §112
Sep 15, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774276
MALT1 Modulators and Uses Thereof
2y 1m to grant Granted Oct 27, 2026
Patent 12767668
IMIDAZOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
3y 5m to grant Granted Oct 20, 2026
Patent 12767644
USE OF 3-ARYLPHTHALIDES AND DERIVATIVES THEREOF AS ANTI-INFLAMMATORY AGENTS
2y 8m to grant Granted Oct 20, 2026
Patent 12758562
SYNTHESIS AND PROCESSING OF POLY(PRO-DRUG) MATERIALS FOR EXTENDED DRUG RELEASE AND USES THEREOF
4y 11m to grant Granted Oct 13, 2026
Patent 12753175
PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE
4y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
91%
With Interview (+18.3%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1794 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month